ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The subjects of new studies on CML patients include the effectiveness of methods like gene expression profiling, next-gen genomics, genetic polymorphisms, multidrug resistance genes, and existing BCR-ABL kinase domain mutations [43].